Rockefeller Capital Management
AVIR icon

Rockefeller Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Rockefeller Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3K Sell
2,214
-2,608
-54% -$13K ﹤0.01% 4006
2026
Q1 		$25.9K Buy
4,822
+3,882
+413% +$17.8K ﹤0.01% 3590
2025
Q4 		$3.36K Buy
+940
New +$2.99K ﹤0.01% 4185
2021
Q4 		– Sell
-3,000
Closed -$105K – 3761
2021
Q3 		$105K Hold
3,000
– – ﹤0.01% 1846
2021
Q2 		$64K Buy
+3,000
New +$90.1K ﹤0.01% 1966

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rockefeller Capital Management's AVIR Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Atea Pharmaceuticals (AVIR) stake by 54% in Q2 2026, selling an estimated $13K and leaving 2,214 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4006.

Rockefeller Capital Management first reported a position in AVIR in Q2 2021 and has held it in 5 quarters since. The position peaked at $105K in Q3 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Rockefeller Capital Management held 2,214 shares of Atea Pharmaceuticals worth $10.3K as of Q2 2026.
  • Rockefeller Capital Management sold 2,608 Atea Pharmaceuticals shares in Q2 2026, an estimated $13K.
  • Atea Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4006 holding.
  • Rockefeller Capital Management first reported a position in Atea Pharmaceuticals in Q2 2021 and has held it in 5 quarters since.
  • Rockefeller Capital Management's Atea Pharmaceuticals position peaked at $105K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.